Bioprocess Technology Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Bioprocess Technology Market Trends and Insights

Expansion in the Biopharmaceutical Industry

Biopharmaceutical sales climbed lifting biologics’ contribution within overall drug spending from 41% in 2024 toward 45% by 2028. FDA projections of up to 20 CGT approvals annually from 2025 underline a new wave of complex modalities that require high-precision, GMP-compliant manufacturing suites. Samsung Biologics’ digital-twin deployment demonstrates how advanced modeling can compress validation timelines while maintaining data integrity.^{[1]Bioprocess International, “Digital Twins Transform Large-Scale Biologics Facilities,” bioprocessintl.com} Capital-intensive upgrades are therefore migrating toward flexible, single-use configurations that accommodate multiple modalities without compromising regulatory expectations.

Growing Contract Development & Manufacturing Outsourcing

The biologics CDMO segment is on course, fueled by large pharma’s strategic divestment of non-core manufacturing assets. Samsung Biologics’ USD 1.4 billion Plant 5 expansion and Lonza’s USD 1.2 billion acquisition of Roche’s Vacaville site (330,000 L) illustrate an arms race for large-scale capacity.^{[2]CHEManager, “Samsung Biologics Breaks Ground on Plant 5,” chemanager.com} Potential passage of the BIOSECURE Act could redirect outsourced volumes from Chinese providers to Western and Korean suppliers; 49% of executives surveyed in 2024 expected stronger contract services growth during 2025. The shift cements the bioprocess technology market as a pivotal enabler of global capacity realignment.

Surge in Cell & Gene Therapy Pipelines

Lonza’s commercial supply pact for CASGEVY, the first CRISPR-edited therapy, exemplifies demand for bespoke viral-vector suites and closed-system cell culture. Standardization remains elusive, yet automation and modular facilities are steadily reducing cost-of-goods. Gene therapy approvals like ELEVIDYS and ROCTAVIAN pushed the market, while the FDA's streamlined approval pathways encourage continued investment. Manufacturing challenges persist, with standardization gaps and workforce shortages creating bottlenecks, yet automation advances and platform process adoption are addressing scalability concerns. The shift from autologous to allogeneic therapies promises enhanced cost-effectiveness and treatment accessibility. 

Rising Demand for Single-Use Bioprocessing Systems

Disposable technologies now dominate commercial biologics production workflows, offering reduced contamination risk and faster changeover versus stainless-steel installations. Thermo Fisher’s 5 L DynaDrive bioreactor boosts productivity by 27% while providing linear scalability up to 5,000 L. WuXi Biologics completed its first 5,000 L PPQ run in Hangzhou, cutting protein cost by 70% and raising yield 20%. Legacy players like GSK invested USD 120 million in Pennsylvania to deploy 2,000 L single-use reactors for complex biologics. 

High Capital Cost of Integrated Systems

Up-front investments for state-of-the-art facilities can exceed USD 500 million, exemplified by Lonza’s planned Vacaville upgrades that target next-gen mammalian platforms. Inflationary pressures have lifted equipment and clean-room construction costs by double-digit percentages since 2023, forcing smaller biotech firms to lean on CDMOs for access to modern capacity.^{[3]Pharma Manufacturing, “Inflation’s Impact on Facility Projects,” pharmamanufacturing.com} Continuous-manufacturing conversions are particularly capital heavy because parallel batch suites must stay online during validation, extending payback horizons. As a result, technology adoption cycles often hinge on demonstrable ROI and regulatory clarity, delaying penetration in cash-constrained geographies. 

Chronic Skilled-Labor Shortages

Eighty percent of biomanufacturing sites reported hiring difficulties in 2024, and Cytiva’s resilience index dipped from 6.27 to 5.60 between 2021 and 2023, reflecting a shrinking specialist pool. Automation proficiency appears in 69% of advertised roles, yet academic curricula seldom provide hands-on exposure to GMP digital systems. The National Institute for Innovation in Manufacturing Biopharmaceuticals found that new hires require up to nine months of supplementary training, adding USD 100,000 per worker in opportunity costs. Employers are reducing degree requirements and introducing in-house academies, but retention remains problematic as industry demand outpaces supply. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Consumables Drive Revenue and Innovation

Consumables and accessories accounted for 60.55% of the bioprocess technology market share in 2025 and are forecast to advance at a 16.42% CAGR through 2031. This growth cements single-use bags, sterile connectors, and custom media as recurring revenue pillars within the bioprocess technology market. Culture media optimized for CGT has underscored value potential, with growing demand for gene-therapy media.

Instrument demand is comparatively steadier, underpinned by innovations such as the 5 L DynaDrive bioreactor and Sartorius’ BIOSTAT RM TX platform for automated cell expansion. Process analyzers are benefiting from heightened PAT adoption as facilities transition toward continuous workflows. The consumables boom embodies the larger structural shift away from stainless-steel dependencies, enabling faster turnarounds and lighter capital footprints across the bioprocess technology market.

By Process Type: Downstream Dominance with Upstream Acceleration

Downstream operations captured 51.20% of bioprocess technology market size in 2025, led by chromatography, filtration, and viral clearance solutions. Chromatography is evolving toward multi-column continuous formats that reclaim resin capacity and buffer efficiency. Upstream, perfusion culture adoption is propelling a 14.55% CAGR, as high cell-density systems cut bioreactor volume requirements while sustaining volumetric productivity.

Planova FG1’s seven-fold performance jump underscores the ongoing innovation race in virus filtration. Yet perfusion systems demonstrated at 2,000 L by Samsung Biologics embody upstream’s acceleration by offering steady-state cultures that pair seamlessly with continuous downstream platforms. These dynamics are tightening integration between unit operations, improving overall facility throughput across the bioprocess technology market.

By Technology: Fed-Batch Leadership with Continuous Processing Emergence

Fed-batch retained 41.90% share of the bioprocess technology market size in 2025 through its regulatory familiarity and extensive installed base. However, continuous setups are expanding at 14.10% CAGR as manufacturers chase smaller footprints and cost-of-goods gains.

ICH Q13 and FDA guidance have lowered adoption barriers, and multi-column chromatography is alleviating downstream bottlenecks in early adopters’ pipelines. Perfusion technologies serve as a pragmatic bridge, delivering continuous cell culture outputs while harvesting in batches to ease regulatory submissions. As more sponsors seek speed-to-clinic, continuous lines are expected to seize a larger slice of future capital budgets, pivoting the bioprocess technology market toward fully integrated, end-to-end continuous architectures.

By Application: Monoclonal Antibodies Lead with CGT Acceleration

Monoclonal antibodies contributed 36.20% of 2025 revenues, driven by expanding oncology and autoimmune portfolios and a steady trickle of biosimilar launches. CGT pipelines, however, are charting the steepest trajectory at a 15.72% CAGR through 2031, buoyed by the FDA’s expectation of approving up to 20 such products each year from 2025.

Lonza’s CASGEVY supply agreement illustrates escalating demand for CRISPR-enabled manufacturing know-how. Recombinant proteins and vaccines preserve diversified demand streams, yet their growth rates trail CGT’s explosive rise as regulatory pathways mature. Collectively, these trends underline the imperative for flexible platforms that can switch between high-titer monoclonal antibody runs and small-volume autologous CGT batches within the same facility footprint.

By End User: Biopharmaceutical Companies Dominate with CMO Growth

Biopharmaceutical sponsors controlled 61.05% of spending in 2025, leaning on internal networks for core franchises. Nonetheless, CMOs are expanding at a 14.75% CAGR as outsourced volumes climb, specifically for complex modalities requiring bespoke suites. Lonza’s integration of Roche’s Vacaville site now offers 330,000 L of capacity, signaling that big-ticket acquisitions remain a primary route to scale.

Academic institutes and government labs supply early-stage discovery work, often partnering with CDMOs for scale-up. The BIOSECURE Act could further pivot outsourcing to Western and Korean vendors, intensifying investment into greenfield builds and accelerating technology refresh cycles across the bioprocess technology market.

Geography Analysis

North America’s 38.90% market leadership is anchored by FDA regulatory depth and an ecosystem of established innovators. GSK’s USD 120 million single-use plant in Pennsylvania and Thermo Fisher’s pending Solventum deal reinforce domestic capacity commitments. Canada’s and Mexico’s cross-border supply chains complement United States strengths, leveraging USMCA provisions for frictionless component trade.

Europe maintains competitive parity through cohesive regulatory frameworks such as the EMA’s revised Annex 1 and upcoming ATMP guidelines, which advocate risk-based sterility assurance. Germany, the United Kingdom, and France provide dense biotech clusters, while Poland and the Czech Republic are capturing spill-over investments through favorable cost structures and EU funding.

Asia-Pacific is the growth pacesetter with an 17.65% CAGR, driven by China’s and South Korea’s extensive greenfield builds. WuXi Biologics’ 15,000 L single-use lines delivered 70% cost savings compared with stainless-steel incumbents. Cytiva’s new 6,100 m² filter plant in Incheon and Samsung Biologics’ digital-twin capacity expansion underscore South Korea’s vaccine hub ambitions. India is pivoting toward global GMP certification but faces infrastructure bottlenecks, prompting domestic firms to invest overseas rather than upgrade local sites. The Middle East, Africa, and South America remain emergent, with Saudi Arabia and Brazil leading nascent biomanufacturing initiatives.

Regulatory Landscape

Regulatory oversight for bioprocess technology is increasingly shaped by frameworks that support modernization of biologics manufacturing while maintaining cGMP expectations. In the United States, the FDA launched the PreCheck Pilot Program in February 2026 to structure early engagement for new domestic manufacturing facilities, reinforcing pre-submission alignment on facility readiness, controls, and data packages for advanced platforms such as single-use and more automated unit operations.

Regulators are also formalizing pathways for continuous and more distributed production models. ICH Q13 (Step 5) provides an internationally recognized foundation for continuous manufacturing of drug substances and drug products, with direct implications for validation strategy, process control, and documentation for biologics. In the EU, the EMA continues to expand its biological medicinal products Q&A set (updated in December 2025, including items such as critical in-process controls and bioburden testing), while its Quality Innovation Group develops considerations for pharmaceutical process models, pointing to higher expectations for model validation as digitalization and advanced process analytics become more prevalent. Complementing these changes, the FDA published a proposed rule in July 2026 to amend drug establishment registration requirements for distributed manufacturing establishments and certain foreign establishments, which can affect compliance practices for networked or modular manufacturing footprints.

Market Opportunities and Future Outlook

Recent investment and capacity moves point to specific whitespace in scalable, flexible biomanufacturing infrastructure and downstream processing capability. Fujifilm Biotechnologies opened expanded facilities in Teesside, England in February 2026 after a GBP 400 million investment, adding 2,000 L and 5,000 L single-use bioreactors that fit the market shift toward multi-product lines and faster changeover operations. Evonik also announced an EUR 80 million investment in April 2026 to expand downstream fermentation capabilities at its Fermas site in Slovenska Lupca, Slovakia, and later outlined a USD 100 million modernization program for its Lafayette, Indiana drug substance site, reinforcing how purification and late-stage processing capacity remain practical bottlenecks and a priority spend area.

A second opportunity zone is FDA-aligned, geographically diversified capacity that supports outsourcing growth and modality expansion, including for cell and gene therapy and other complex biologics. Samsung Biologics reported a U.S. footprint step in April 2026 through the acquisition of a Rockville, Maryland biomanufacturing site for USD 280 million, adding 60,000 L of cGMP capacity, while Bora Biologics expanded its U.S. platform with a Rockville facility and cited 20,000 L of installed single-use bioreactor capacity across two FDA-registered sites. As sponsors and CDMOs broaden their networks, demand is concentrating on standardized single-use consumables, closed-system unit operations, and QC-ready analytics that can shorten tech transfer and validation cycles across regions.